Introduction
B-cell chronic lymphocytic leukemia (CLL) is one of the most common types of adult leukemia in western countries, with an estimate of 15 110 new cases and 4390 deaths in the United States in 2008. 1 Mainly affecting elderly people, CLL is a heterogeneous disease that varies considerably with respect to disease progression, therapeutic response and clinical outcome. The Rai and Binet staging systems have been essential tools to assess prognosis and to make treatment decisions. 2 In recent years, the prognostic values of several biologic markers have been investigated. Among these markers, deletion of the chromosome region 17p13, which contains tumor suppressor gene TP53, is strongly and consistently associated with rapid disease progression and short survival. 3 Recent data from prospective trials have confirmed this observation and have also shown that deletion of 17p is associated with resistance to conventional DNA-damaging chemotherapies. [4] [5] [6] [7] Other biologic markers, such as 11q deletion, unmutated IgV H , ZAP70 and CD38, are also associated with inferior prognosis. 8 The role of these prognostic factors in patient management is being investigated.
For patients with early-stage, nonprogressive, asymptomatic CLL, a wait-and-watch approach is used, whereas patients with symptomatic and advanced CLL usually require treatment. Since the 1990s, purine analogs, in particular fludarabine, have mostly replaced the alkylator chlorambucil as first-line treatment for CLL. 9 More recently, purine analog-based combination regimens, such as FC (fludarabine plus cyclophosphamide), FCR (FC plus rituximab), CC (cladribine plus cyclophosphamide), PCR (pentostatin, cyclophosphamide and rituximab), FCM (FC plus mitoxantrone) and FCM-R (FCM plus rituximab), have been investigated as first-line treatment for CLL. [4] [5] [6] [7] [8] [10] [11] [12] [13] Compared with single-agent therapy, combination regimens produce both improved overall and complete response rates and longer progression-free survival (PFS).
Despite improved response rates to purine analog-based first-line therapies, the quality of responses remains suboptimal, as nearly all patients will eventually relapse. In addition, there are some patients for whom purine analog-based therapies may be inappropriate, such as those with renal insufficiency (purine analogs are eliminated predominantly via the kidney). Alternative therapies are therefore needed to treat these patients. Nonchemotherapeutic agents, including monoclonal antibodies, glucocorticoids, other small-molecule agents, vaccines and cellular immunotherapy, are playing an increasingly important role in CLL therapy. In this article, we review the nonchemotherapeutic agents currently used in the treatment of CLL and discuss the rationale and available data on the combination of these agents. Key data on single-agent nonchemotherapeutic therapies in CLL are summarized in Table 1. 14-22
Monoclonal antibodies

Alemtuzumab
Currently, alemtuzumab is the only monoclonal antibody approved for the treatment of CLL, with indications in both first-line and relapsed/refractory settings. Alemtuzumab is a humanized monoclonal antibody against CD52, which is a membrane glycoprotein highly expressed in normal and malignant lymphocytes, monocytes and macrophages, but not in hematopoietic progenitor cells. 23 In a recent randomized phase III study by Hillmen et al., 15 single-agent alemtuzumab (30 mg, intravenous, three times per week for up to 12 weeks) was compared with chlorambucil (40 mg/m 2 , every 28 days for up to 12 months) in patients with previously untreated CLL. The overall response rate (ORR) was 15 Alemtuzumab is also effective in patients in whom fludarabine has failed. In a pivotal phase II trial of 93 patients with fludarabine-refractory disease, alemtuzumab induced an ORR of 33% (CR of 2%, partial response (PR) of 31%). The median time to progression (TTP) was 4.7 months, and median overall survival was 16 months.
14 Furthermore, alemtuzumab is one of the few agents that have been shown to be no less effective in patients harboring 17p13 deletion and/or p53 defects. [24] [25] [26] [27] Although alemtuzumab therapy is associated with cytopenia and increased infection rates, particularly a higher rate of cytomegalovirus (CMV) reactivation, 14 data from Hillmen et al. 15 showed that alemtuzumab can be safely used as a frontline therapy for CLL and that the incidence of serious adverse events (AEs) other than CMV reactivation was no higher in patients receiving alemtuzumab than those receiving chlorambucil. Symptomatic CMV infection was detected in 15.6% of patients receiving alemtuzumab, but no end-organ involvement was observed, and all patients recovered after treatment interruption and intravenous ganciclovir therapy. 15 
Rituximab
Rituximab is a chimeric monoclonal antibody against CD20, which is expressed in normal and malignant B cells. 28, 29 Rituximab is approved for the treatment of CD20-positive follicular non-Hodgkin's lymphoma. Although single-agent rituximab is highly effective for follicular non-Hodgkin's lymphoma, it is less effective for CLL. Hainsworth and colleagues 17 reported an ORR of 58% and a CR rate of 9% in patients with previously untreated CLL. The median PFS was 18.6 months after a median follow-up of 20 months. Several small trials have evaluated the activity of single-agent rituximab at a standard dosage (375 mg/m 2 weekly for 4 weeks) in patients with relapsed/refractory CLL. In these trials, ORR was 15-25% (no CR), and the median response duration was 20 weeks. 16, 30 Higher response rates (ORR 36-45%) were achieved with higher doses of rituximab. 31, 32 Because rituximab has modest efficacy as a single agent in the treatment of CLL, the majority of studies on rituximab over the past 10 years have been with combination therapy, such as FR (fludarabine plus rituximab) and FCR.
Adverse events associated with single-agent rituximab are generally mild, except for cytokine release syndrome in patients with high lymphocyte counts that often accompanied the initial dose. 33 In patients with high lymphocyte counts or bulky lymphadenopathies, careful monitoring of renal function, appropriate hydration and concomitant administration of allopurinol are recommended.
New anti-CD20 antibodies
Several next-generation anti-CD20 antibodies are being developed as therapy for B-cell lymphoproliferative disorders. These new anti-CD20 antibodies are generated through antibody engineering and have improved features such as lower immunogenicity or higher affinity to Fc receptor FcgRIIIa. 34 Of these antibodies, ofatumumab (HuMaxCD20) has entered latestage clinical development.
Ofatumumab is a fully human anti-CD20 monoclonal antibody that binds to an epitope different from that targeted by rituximab and has enhanced complement-dependent cytotoxicity against B-cell lines in vitro, as compared with rituximab. Binding of ofatumumab redistributes CD20 antigen into lipid raft regions (same as rituximab), but the dissociation rate of ofatumumab is significantly lower than that of rituximab. 35 Safety and efficacy of single-agent ofatumumab in relapsed/ refractory CLL have been studied in a phase I/II trial. The highest dose in this trial was one 500 mg and three 2000 mg infusions once weekly. The maximum tolerated dose was not reached. At the highest dose level, ORR was 50% (PR 42% and nodular PR (nPR) 8%). 36 Ofatumumab was generally well tolerated, with serious AEs in 9 of 33 treated patients. Ofatumumab monotherapy is currently being investigated in a phase III pivotal trial in patients with CLL in whom both fludarabine and alemtuzumab have failed (ClinicalTrials.gov NCT00349349) and also as frontline therapy in combination with fludarabine and cyclophosphamide (ClinicalTrials.gov NCT00410163).
Lumiliximab
Lumiliximab is a chimeric macaque-human monoclonal antibody directed against CD23, a low-affinity IgE receptor that is expressed in several hematopoietic cell types including CLL. 37, 38 Lumiliximab induces cell death in primary CLL cells mainly through apoptosis and does not show appreciable complement-dependent cytotoxicity or antibody-dependent cell-mediated cytotoxicity (ADCC) activity toward CLL cells. 39 Lumiliximab induces apoptosis through the downregulation of antiapoptotic proteins Bcl-2, Bcl-X L and X-linked inhibitor of apoptosis protein (XIAP), the activation of proapoptotic protein Bax and the release of cytochrome c. 39 In a phase I/II trial in patients with relapsed/refractory CLL, lumiliximab in combination with FCR produced an ORR of 71% (CR 48%, PR 10% and unconfirmed PR 13%), and it did not seem to increase the toxicity of the FCR regimen. 40 Compared with historical data on FCR alone, 41 the CR rate achieved with lumiliximab plus FCR appears to be higher. On the basis of this result, lumiliximab is currently being investigated in a randomized phase III trial (FCR vs FCR plus lumiliximab) in patients with relapsed/refractory CLL.
High-dose glucocorticoid therapy
It has long been known that glucocorticoids kill lymphocytes, including CLL cells, by apoptosis and that such cell death is p53 independent. 42 Because p53 defects are strongly associated with chemoresistance in CLL, glucocorticoids are therefore a logical treatment option for patients with 17p deletion and/or p53 defects.
High-dose methylprednisolone (HDMP) was investigated in patients with refractory CLL. 18 Among 11 treated patients, 6 achieved PR and none achieved CR. The median duration of response was 8 months. HDMP was generally well tolerated. Side effects included fluid retention, hyperglycemia, bradycardia, herpes simplex infection and pneumonia. HDMP, either alone or in combination with chemotherapy, was also evaluated in CLL with p53 abnormalities. 19 Among 25 treated patients, 10 (45%) had p53 abnormalities. The ORR was 77%, and the median duration of response was 12 months. There was no difference in response rate whether HDMP was used alone or in combination with chemotherapy. Of the 10 patients with p53 abnormalities, 5 patients responded, including 2 with nPR. The most serious AE was infection, which occurred in seven patients. These clinical data support the idea that glucocorticoids have useful clinical activity in CLL and are no less effective in patients with p53 defects.
Immunomodulatory drugs
Immunomodulatory drugs are a class of small-molecule agents that are being developed for the treatment of various diseases including CLL. Starting from thalidomide, a series of analog compounds have been developed. Of these compounds, lenalidomide has been investigated most intensively. Lenalidomide has a wide range of immunomodulatory activities, including stimulation of T cells through CD28, enhanced expression of cytokines interleukin-2 (IL-2) and interferon-g by T cells, and augmented natural killer (NK) cell cytotoxicity and ADCC. In addition, lenalidomide also has growth inhibitory and proapoptotic activities. 43 Recent studies have shown that lenalidomide can reverse the impaired immune synapse formation in T cells from patients with CLL, 44 and that it can also act directly on CLL cells through the upregulation of the B-cell activation markers CD40 and CD86. 45 Lenalidomide has been approved for the treatment of multiple myeloma and myelodysplastic syndrome with the 5q deletion cytogenetic abnormality.
The efficacy and safety of lenalidomide have been evaluated in patients with CLL. In one study, 45 patients with relapsed/ refractory CLL received oral lenalidomide (25 mg daily on days 1-21 of a 28-day cycle). The ORR was 45%, with a CR rate of 9% and a PR rate of 38%. Median PFS was not reached, and the estimated PFS at 1 year was 81%. Lenalidomide was effective in patients harboring 11q deletion (ORR 47%) and in patients with bulky disease (ORR 40%). 20 In another study, 44 patients with relapsed/refractory CLL were given oral lenalidomide at a starting dose of 10 mg daily for 28 days. On the basis of patient tolerability and response, the dose was then increased by 5 mg increments every 28 days to a maximum dose of 25 mg daily. The ORR was 32%, with 3 patients (7%) achieving CR, 1 patient (2%) nPR and 10 patients (25%) PR. Lenalidomide was effective in patients with unfavorable prognostic markers; an ORR of 31% was achieved in patients with 11q or 17p deletion, 24% in patients with unmutated IgV H and 25% in patients with fludarabine-refractory disease. 21 Lenalidomide therapy was associated with an increase in plasma levels of inflammatory cytokines and cytokine receptors such as IL-2, IL-6, IL-10 and tumor necrosis factor receptor 1, whereas no change in the plasma level of vascular endothelial growth factor was observed. 21 Despite its promising activity in CLL, toxicity remains an issue for lenalidomide. In a recent report, Andritsos and colleagues 45 described life-threatening tumor flare reaction and tumor lysis syndrome in patients with CLL treated with highdose lenalidomide (25 mg/m 2 /day for 21 days of a 28-day cycle), showing the need for careful monitoring of renal function and adequate prophylaxis of tumor lysis during treatment. A phase I/ II study is ongoing to establish a safe dosing schedule for this agent in CLL.
Agents with intracellular molecular targets
Bortezomib
Proliferation and survival of malignant cells depend on constitutive degradation of important antiproliferative proapoptotic proteins through the ubiquitin-proteasome system. 46 Therefore, inhibition of the ubiquitin-proteasome system is an attractive anticancer strategy. Bortezomib is a potent, specific proteasome inhibitor that has been approved for the treatment of multiple myeloma and mantle cell lymphoma.
In a phase II study of single-agent bortezomib in fludarabinerefractory CLL, 22 patients were treated. Of 19 evaluable patients, no CR or PR was observed, although disease site responses (for example, reduction in lymphocytosis, splenomegaly and lymphadenopathy) were observed. Grade 3/4 AEs included anemia, neutropenia, dyspnea and vomiting and were generally predictable and manageable. 47 The role of bortezomib in the treatment of CLL remains to be defined.
Oblimersen
Bcl-2 is a mitochondrial antiapoptotic protein that is frequently upregulated in various human malignancies. Upregulation of Bcl-2 expression in CLL may be mediated by promoter hypomethylation 48 or loss of miR-15 and miR-16, the miRNA regulators of Bcl-2. 49 Expression of Bcl-2 correlates with the susceptibility of CLL cells to apoptosis-inducing agents in vitro, as well as with clinical outcome. 50 Oblimersen is a Bcl-2-specific antisense oligonucleotide. A randomized phase III trial evaluating oblimersen in combination with FC in patients with relapsed/refractory CLL was recently completed. 51 Of patients in the oblimersen plus FC group, 17% of patients achieved CR/nPR, as compared with 7% in the FConly group. ORR was not significantly different between the two groups. Although TTP and survival were not significantly different between the two groups, in patients with a good response (CR/nPR), oblimersen treatment correlated with longer TTP and longer survival.
Flavopiridol
Flavopiridol is a semisynthetic and potent inhibitor that targets cyclin-dependent kinases (CDK1, 2, 4 and 7). It was originally developed as a cell cycle inhibitor that blocks cells at the G1/S and G2/M boundaries. 52 Recently, novel mechanisms of action have been recognized for this drug that include transcriptional inhibition mediated through the disruption of CDK9/cyclin T complex and the induction of apoptosis mediated partly through impaired oxygen consumption and mitochondrial damage. 53, 54 Although in vitro studies of flavopiridol had showed impressive activity, early clinical trials were disappointing. Flinn et al. /day via 72-h CI every 2 weeks, no response was observed. Among 36 patients who received flavopiridol at a dose of 50 mg/m 2 via 1-h intravenous bolus every 3 weeks, only 4 patients (11%) had a PR. 56 It was later recognized that preferential binding of flavopiridol to human serum protein requires a much higher drug concentration in human serum than in bovine serum for the drug to be effective. A revised dosing schedule (50% dose via 30-min bolus followed by 50% dose via 4-h infusion, 4 weekly doses of 60-80 mg/m 2 ) was designed to increase an effective drug concentration in patients and showed significant activity. Of 42 patients treated, 45% had PR, including 42% in patients with 17p deletion and 72% in patients with 11q deletion. 22 
Nonchemotherapy combination therapy for CLL S Faderl et al
Vaccines and cell-mediated immunotherapies
The induction of T cell-mediated immune response against cancer cells has been an attractive antitumor strategy. However, the induction of antitumor immune response in patients with CLL is challenging due to profound immune deficiency associated with the disease. Investigators have used various approaches to manipulate the immune system, with the aim to correct the immune defects in patients with CLL. Two recent articles have provided excellent reviews on vaccine and cellmediated immunotherapy strategies for CLL, 57, 58 and here we will only briefly discuss some select therapies.
Several vaccine approaches have been developed for CLL. These vaccines are based on tumor-associated antigens that are selectively expressed or mutated in tumor cells but not in normal cells. Of all tumor-associated antigens, the idiotypic immunoglobulin (Id) is the most extensively studied. Each B-cell expresses an Id molecule with unique variable regions in the heavy and light chains. Therefore, each patient with CLL has his/ her signature Id tumor antigen that is inherited from the normal B-cell progenitor. 58 An investigational vaccine has been developed by conjugating patient-derived Id peptide with keyhole limpet hemocyanin, an immunogenic carrier protein. This vaccine, in combination with granulocyte-macrophage colony-stimulating factor, is currently being evaluated in an ongoing phase I/II trial for safety and immunologic efficacy (ClinicalTrial.gov identifier: NCT 00302861).
Cell-mediated immunotherapies including dendritic cell therapies and activated T-cell therapies are also being actively investigated. A clinical study of dendritic cell therapy in nine patients with CLL has been reported. 59 Dendritic cells were derived from monocytes of unrelated healthy donors and stimulated with lysates or apoptotic bodies from patient-specific CLL cells. Stimulated dendritic cells were then injected intradermally into corresponding patients once every 2 or 3 weeks. Decreases in peripheral leukocyte count and CD5 þ / CD19 þ leukemic cell count were observed; no autoimmunity was observed, and skin reactions were mild. Kipps and colleagues 60 reported the clinical results of an ex vivo autologous T-cell activation therapy. T cells were isolated from patients with CLL and cultured on magnetic beads coated with monoclonal antibodies against CD3 and CD28 in the presence of IL-2. Activated T cells were infused back into the donor patient. A dose-dependent increase in blood T-cell counts and improvements in neutropenia, thrombocytopenia and anemia were observed, although a reduction in circulating leukemic cells was not seen.
Rationale for nonchemotherapeutic combination therapy
Mechanistic synergy
Mechanisms of action of current nonchemotherapeutic agents are summarized in Table 2 . Combining agents that use complementary mechanisms of action may exploit mechanistic synergy and offer new therapeutic opportunities. For example, the downregulation of CD20 expression was observed in five of nine patients with CLL refractory to rituximab and fludarabine. The downregulation of CD20 expression was associated with improved clinical response to alemtuzumab therapy; CR was achieved in three of five patients with CD20 downregulation, as compared with one of four patients with steady CD20 levels. 61 Therefore, the combination of rituximab and alemtuzumab may have a better chance to achieve good response than either antibody alone. Another example of mechanistic synergy is lenalidomide and monoclonal antibody combination. Lenalidomide stimulates NK cell-mediated ADCC and may enhance the ADCC activity of therapeutic monoclonal antibodies.
Deletion of 17p and/or mutation in the TP53 gene result in loss of the function of p53, a key regulator of cell cycle checkpoint, DNA damage response and apoptosis. 62 Loss of p53 underlies resistance to conventional chemotherapy in patients harboring these genetic abnormalities. Alemtuzumab, glucocorticoids, lenalidomide and flavopiridol are among the few agents that are known to be no less effective in patients with p53 defects. Combinations of these agents may produce better results in patients with p53 defects than does monotherapy.
Anatomical considerations
Chronic lymphocytic leukemia is a disease involving the blood, bone marrow and lymph nodes. A good response relies on the elimination of CLL cells from all major disease sites. Interestingly, current single-agent therapies have differential activities in these disease sites. Proper combination of single-agent therapies may improve the efficacy in all major sites and induce higher quality remission. For example, alemtuzumab is very effective in eradicating disease in peripheral blood and bone marrow but less effective in resolving bulky lymphadenopathy.
14 On the other hand, HDMP is very effective at reducing lymphadenopathy. 19 The combination of alemtuzumab with HDMP would therefore be a logical treatment strategy to achieve optimal response in both bone marrow and lymph node compartments.
Safety considerations
Safety is often an important consideration in devising combination treatment strategies. The pivotal question that physicians need to answer is whether improved efficacy of combination therapy outweighs the risk of increased toxicity. It is likely that the toxicity of combination therapy will depend on individual treatment regimen and patient/disease profile. Some combinations are expected to have toxicity not exceeding that of singleagent therapies (for example, alemtuzumab plus rituximab). Other combinations may have increased toxicity but may still be beneficial for patient subgroups for which no other optimal treatments exist. By conducting clinical trials carefully designed to address safety questions, investigators will be able to identify combination regimens that offer optimal balance between efficacy and safety.
Current clinical data on nonchemotherapeutic combination therapy
In this section, we provide an overview of published studies of nonchemotherapeutic combination regimens. Key clinical data from these studies are summarized in Table 3 .
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Alemtuzumab plus rituximab
Both alemtuzumab and rituximab are effective monoclonal antibody therapies for CLL and are widely used in clinical practice. As a logical combination strategy, combination of these two antibodies has been investigated by several groups.
Faderl et al. treated 48 patients with relapsed/refractory lymphoid malignancies (32 patients with CLL). The regimen consisted of rituximab (375 mg/m 2 weekly for 4 weeks) and alemtuzumab (3-, 10-and 30-mg dose escalation in week 1, followed by 30 mg twice a week in weeks 2-4). 63 In the 32 patients with CLL, the ORR was 63% (CR 6%, nPR 6% and PR 50%). No significant difference in response was observed between patients with fludarabine-sensitive disease and patients with fludarabine-refractory disease. With a median follow-up of 6.5 months, the median TTP was 6 months and median overall survival was 11 months. The regimen was well tolerated. Overall 50% of patients had at least one infectious episode, but the incidence of infection was no higher than what would be expected with single-agent alemtuzumab, and there was no fatal infection. Because alemtuzumab frequently causes infusion-related reactions, a follow-up study was conducted to evaluate a modified dosing schedule of the alemtuzumab-rituximab combination therapy with the aim to reduce infusion-related AEs. 64 Dose escalation of alemtuzumab was administered through CI, and subsequent alemtuzumab was administered subcutaneously. In 20 patients evaluable for response, the ORR was 55% (CR 30%, nPR 5% and PR 20%). All responders achieved maximum response by 4 weeks of therapy (one course). Infections were recorded in 50% of patients, including CMV reactivation in 21% of patients. Alemtuzumab given via CI was better tolerated than via bolus infusion.
Nabhan et al. 65 evaluated alemtuzumab plus rituximab in 12 patients in whom fludarabine-based therapy had failed. The regimen consisted of 4 weekly doses of rituximab at 375 mg/m 2 (weeks 1, 3, 4 and 5) and alemtuzumab three times a week on weeks 2 through 5 (three patients at 3 mg, three patients at 10 mg and six patients at 30 mg). In 11 patients who were evaluable for response, one PR that lasted for 10 weeks was observed. The other 10 patients had stable disease that lasted for a median duration of 3.4 months. All patients had a normalized absolute lymphocyte count at a median of 23.5 days after the start of therapy, and five of six patients at the 30-mg alemtuzumab dose level had minor responses in lymphadenopathy and splenomegaly. The treatment was well tolerated. No significant myelosuppression or CMV infection or reactivation was observed.
The alemtuzumab plus rituximab combination was recently evaluated as first-line treatment in previously untreated patients. A phase II trial investigated this combination in patients who had early-stage (Rai stage 0-II), high-risk (defined as having one or more of the following: 17p13 deletion, 11q22 deletion or unmutated IgV H (o2%) and the expression of ZAP70 (X30%) and/or CD38 (X20%)) CLL and who did not meet the National Cancer Institute Working Group (NCI-WG) 1996 criteria for treatment. 66 Treatment consisted of one 30-day cycle (alemtuzumab dose escalation on days 1-3, then 30 mg TIW (three times a week) for 4 weeks with all doses administered subcutaneously and rituximab at 375 mg/m 2 QW (every week) for 4 weeks). Of 30 treated patients, 27 were evaluated for response. The ORR was 93% (CR 44%, nPR 30% and PR 19%). The median TTP in responders was 14.4 months after a median follow-up of 14.1 months. Six patients with CR were negative for minimal residual disease as measured by three-color flow cytometry, and all remained in CR. A first-line alemtuzumab plus rituximab therapy was safe. Grade 3/4 nonhematologic toxicity occurred in only three patients (two reactions to prophylaxis drug, and one CMV reactivation that responded to intravenous ganciclovir therapy).
In another study, Frankfurt et al. 67 evaluated a different dosing schedule of alemtuzumab plus rituximab in previously untreated patients. Subcutaneous alemtuzumab was given at 30 mg TIW for 17 weeks after subcutaneous dose escalation, and rituximab was given at 375 mg/m 2 every other week for eight doses starting on week 3. A total of 13 patients were enrolled, and analyses were available for 11 patients. According to the NCI-WG 1996 criteria, all patients responded, with eight CR (72%) and three PR (28%). Nine patients (81%) were MRD-negative at the end of the study, as assessed by flow cytometry. The median duration of response was not reached after a median follow-up of 15 months. Four patients had CMV reactivation, but none suffered organ involvement, and all responded to ganciclovir therapy. There were no other serious infections.
Data from these studies suggest that alemtuzumab plus rituximab has superior efficacy, as compared with either antibody alone, in both relapsed/refractory and previously untreated CLL patients. The combination is well tolerated, with acceptable toxicities.
Alemtuzumab plus HDMP
Pettitt et al. 68 reported a case series of a combination therapy of alemtuzumab plus HDMP in patients with CLL harboring p53 defects, three of whom had relapsed/refractory disease. The regimen consisted of up to four 28-day cycles, each cycle having intravenous methylprednisolone (at a dose of 1.0 g/m 2 per day on days 1-5) and alemtuzumab (30 mg TIW after an initial week of dose escalation). Alemtuzumab was given intravenously during cycle 1 and subcutaneously thereafter. All five treated patients had clinically aggressive disease and bulky lymphadenopathy. Three patients achieved CR (two MRD negative and one MRD positive), and each one patient achieved nPR and PR, respectively. All patients eventually had disease progression after a median of 9 months (range, 4-18) (unpublished data). All five patients experienced infections during therapy, but all were successfully treated. It should be noted that four of the five patients were already at very high risk of infection either because they had been heavily pretreated or because they had a prior history of infection. Hematopoietic toxicities were modest and transient, in keeping with the effects of alemtuzumab alone.
Rituximab plus HDMP
A retrospective study of rituximab plus HDMP combination therapy was published recently. 69 A total of 37 patients with relapsed CLL were identified for this study. The dose and schedule for the combination therapy were not uniform. The most frequently used regimen was methylprednisolone (1 g/m 2 on days 1-5) and rituximab (375 mg/m 2 on days 1, 8, 15 and 22 every 4 weeks). The median number of cycles administered was 1 (range, 1-3). In the 37 treated patients, the ORR was 78% (CR 22% and PR 57%). It can be noted that the rituximab-HDMP combination was effective in patients with unfavorable cytogenetics or bulky lymph nodes. Of the nine patients with 17p deletion, five had PR; of the six patients with 11q deletion, two had CR and two had PR. Of the eight patients with bulky lymph nodes (45 cm), two had complete resolution of lymphadenopathy and four had at least 50% reduction in their nodes. The median PFS was approximately 1 year, and 3-year survival rate was 41%. Infectious complications occurred in 29% of patients during treatment or within 4 weeks after the first cycle. Five patients died of infectious complications during the first month of their treatment. All of these five patients had serious comorbid diseases in addition to advanced CLL.
Dungarwalla et al. 70 investigated the rituximab-HDMP combination therapy in 14 patients with advanced, heavily pretreated CLL. Twelve patients had bulky lymph nodes, and 13 patients had received prior fludarabine treatment. The regimen was methylprednisolone (1 g/m 2 daily on days 1-5) and rituximab (375 mg/m 2 on day 1 of a 28-day cycle for up to 6 cycles). Eight patients completed six cycles of treatment. The ORR was 93%, including two patients with CR and one patient with nPR. The median PFS was 7 months, and median overall survival was 20 months. Opportunistic infections such as Aspergillus and Candida were common in this study, and the authors discussed the potential use of itraconazole or posaconazole prophylaxis to better control these opportunistic infections.
The future of nonchemotherapy combinations in CLL Purine analog-based combination chemotherapy or chemoimmunotherapy is considered by many to be a highly effective firstline therapeutic option. However, nonchemotherapy combination therapies are likely to play an increasingly important role in certain patients for whom conventional chemotherapy is unlikely to work or is contraindicated due to comorbidity. Nonchemotherapeutic agents, such as rituximab, alemtuzumab and glucocorticoids, have mechanisms of action that are distinct from those of chemotherapeutic agents and may overcome resistance mechanisms. Combination of these nonchemotherapeutic agents may also be useful as second-line therapy for patients with CLL in whom purine analog-based chemotherapy has failed.
Several clinical trials of nonchemotherapy combinations are ongoing or being planned. In the United Kingdom, the NCRI CLL206 trial of alemtuzumab plus HDMP ('Cam-Pred') for patients with 17p
À CLL has recently completed recruitment, and a follow-up study (NCRI CLL210) is planned in which patients who respond to Cam-Pred will receive lenalidomide maintenance if allogeneic transplantation is not feasible or appropriate. Other trials include alemtuzumab plus rituximab (Dana-Farber Cancer Institute, Boston, MA, USA), alemtuzumab plus rituximab plus granulocyte-macrophage colony-stimulating factor in high-risk patients (Mayo Clinic, Rochester, MN, USA), subcutaneous alemtuzumab plus oral dexamethasone (GCLLSG CLL2O), alemtuzumab plus lenalidomide (Karolinska Hospital, Stockholm, Sweden) and rituximab plus lenalidomide (CLL Research Consortium). The results of these trials will be eagerly awaited. Novel nonchemotherapeutic combination regimens are emerging from new and existing agents and may further complement existing therapies for CLL.
